Scarica l'app Stockscreener
78.00
2.16%
1.75
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Illumina Inc Borsa (ILMN) Ultime notizie
June 6th Options Now Available For Illumina (ILMN) - Nasdaq
It’s all about accessibility: Developing technical training for the MiSeq i100 Series - Illumina
Should You Hold Illumina (ILMN)? - Yahoo Finance
Veraxa makes a SPAC deal; Illumina discloses layoffs - Endpoints News
Resmed Taps Illumina Exec for Chief Investor Relations Officer Role - Medical Product Outsourcing
Microarray Market Projected To Witness Massive Growth, 2025-2032 | Thermo Fisher Scientific Inc.,Illumina Inc. - openPR.com
DNA Microarray Technology Market: Innovations & Opportunities - openPR.com
Cancer Biopsy Market Detailed In New Research Report 2025 | - openPR.com
Genomic Cancer Testing Market Overall Study Report 2025-2032 | - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Thomas Kean Jr purchases shares in Illumina and nVent Electric - Investing.com Australia
Resmed Names Salli Schwartz as Chief Investor Relations Officer - The Manila Times
Resmed Names Salli Schwartz as Chief Investor Relations Officer - GlobeNewswire Inc.
Illumina, Inc. (ILMN): Among Recent Activist Investor Campaigns - Insider Monkey
Controlling Genes Market Detailed in New Research Report By 2032 - openPR.com
Illumina (ILMN) Receives a Buy from Leerink Partners - The Globe and Mail
Illumina, Tempus AI partner to drive genomic testing beyond cancer - MedTech Dive
Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks - Yahoo Finance
DNA Methylation Market Deep Research Report with Forecast by 2032 | Illumina, Inc.,Thermo Fisher Scientific - openPR.com
RNA Sequencing Market Size, Share, Outlook, Industry Analysis, - openPR.com
MicroRNA Market Size, Share, Trends, Opportunities, - openPR.com
AI in Omics Studies Market Overall Study Report 2025-2032 | Thermo Fisher Scientific, Agilent Technologies, Illumina - openPR.com
Illumina, Tempus AI To Collaborate To Accelerate Genomic AI Innovation - Nasdaq
Illumina and Tempus join forces to expand genomic testing By Investing.com - Investing.com India
Illumina, Tempus AI Collaborating to Accelerate Clinical Use of Sequencing Tests - marketscreener.com
Illumina And Tempus Partner To Drive The Future Of Precision Medicine Through Genomic Ai Innovation - MarketScreener
Illumina and Tempus join forces to expand genomic testing - Investing.com
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation - PR Newswire
BofA Securities Cuts Price Target on Illumina to $75 From $90, Keeps Underperform Rating - MarketScreener
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc.(ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Illumina (NASDAQ:ILMN) Price Target Cut to $112.00 by Analysts at Royal Bank of Canada - MarketBeat
Illumina : Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development - MarketScreener
Personalized Medicine Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La RocheResearchAndMarkets.com | FinancialContent - FinancialContent
Illumina To Announce First Quarter 2025 Financial Results On Thursday, May 8, 2025 - MarketScreener
Shareholders in Illumina (NASDAQ:ILMN) have lost 77%, as stock drops 6.8% this past week - simplywall.st
Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025 - Yahoo Finance
Single-cell Omics Emerging Technologies and Markets Report 2025: 10x Genomics, Thermo Fisher & Illumina Lead $9.1 Billion Single-cell Omics Market by 2029 - Yahoo Finance
Cancer Profiling Market Positioned for Accelerated Growth with - openPR.com
Illumina (ILMN) Receives a Sell from Barclays - The Globe and Mail
Corvex’s Meister joins the board at Illumina. Here’s how he can create value for shareholders - MSN
Genotyping Assay Market Surges to USD 37.1 Billion by 2029: - openPR.com
Biotechnology company Illumina names Julie Hiner as comms head - Medical Marketing and Media
PacBio to cut jobs, lower spending over NIH funding cuts and tariffs - MarketScreener
DNA Data Storage Market to See Booming Growth 2025-2032 | Illumina, Inc.,Microsoft,Iridia, Inc.,Twist Bioscience - openPR.com
DNA Sequencing Technologies Market Deep Research Report with - openPR.com
Admera Health uses the NovaSeq X Plus to expand capabilities - Illumina
RBC Cuts Price Target on Illumina to $112 From $128, Keeps Outperform Rating - MarketScreener
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Where are the Opportunities in (ILMN) - news.stocktradersdaily.com
Deep Dive Into Illumina Stock: Analyst Perspectives (14 Ratings) - Benzinga
Apple To $250? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
How Do Investors Really Feel About Illumina? - Benzinga
California Public Employees Retirement System Reduces Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Epigenetics Market Deep Research 2025-2032 | Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited - openPR.com
Illumina stock hits 52-week low at $70.88 amid market challenges - Investing.com
INVESTOR ALERT: Levi & Korsinsky Notifies Illumina, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineILMN - ACCESS Newswire
0.05%
3.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):